Previous 10 | Next 10 |
home / stock / rhhby / rhhby news
2024-04-07 08:00:00 ET More on Phathom Pharmaceuticals Phathom: Undervalued Biotech With Possible GERD Treatment Label Expansion Phathom Pharmaceuticals, Inc. (PHAT) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Phathom Pharmaceuticals ...
2024-04-04 13:11:10 ET More on ADC Therapeutics ADC Therapeutics: Real Opportunity With Real Risk In 2024 (Rating Upgrade) ADC Therapeutics SA (ADCT) Q4 2023 Earnings Call Transcript ADC Therapeutics SA 2023 Q4 - Results - Earnings Call Presentation Seeking A...
2024-04-01 10:17:11 ET More on Solid Biosciences Solid Biosciences: DMD Treatment Advancement With Next-Generation Capsid William Blair starts Solid Biosciences at outperform Piper Sandler upgrades Solid Biosciences to overweight Seeking Alpha’s Quant ...
2024-03-31 09:25:35 ET Summary The positive CHMP opinion could mean possible European Approval; European Commission expected to decide upon approval for this in the next few months. Phase 3 NORSE EIGHT study underway using ONS-5010 for the treatment of patients with Wet-AMD; Data ...
2024-03-25 13:47:00 ET Summary Boeing's top boss Dave Calhoun plans to step down at the end of the year. Mizuho turns cautious on the EV sector, downgrades Tesla, Rivian, and Nio. Look beyond the Magnificent 7 to the GRANOLAS in Europe - Goldman Sachs. Listen below o...
2024-03-24 13:38:10 ET More on the GRANOLAS Sequoia Fund - SAP SE: We See A Clear Path To Enhanced Profitability ASML: Don't Be Fooled Into Buying Its Overvalued Shares Now What AstraZeneca Is Getting Through The Acquisition Of Fusion Pharmaceuticals Mo...
2024-03-22 09:30:41 ET Summary Tourmaline Bio, Inc.'s share price dropped by 37% after Chugai's Enspryng, an IL-6 blocker, failed to meet expectations in a study on myasthenia gravis. Tourmaline is developing TOUR006, its own IL-6 blocker, for thyroid eye disease and atherosclerot...
2024-03-21 07:00:09 ET More on Argenx SE argenx SE (ARGX) Q4 2023 Earnings Call Transcript argenx: Upgrading To 'Strong Buy' On Vyvgart's Q4 Sales, Empasiprubart Data, Pipeline Expansion Argenx SE GAAP EPS of -$1.68 misses by $0.30, revenue of $374M beats by $10.28M ...
2024-03-20 06:14:16 ET Swiss contract drug manufacturer Lonza ( OTCPK:LZAGF ) ( OTCPK:LZAGY ) has agreed to acquire a large-scale biologics manufacturing site in California from Roche ( OTCQX:RHHBY ) ( OTCQX:RHHBF ) for $1.2B in cash.... Read the full article on Seekin...
2024-03-19 06:46:45 ET Summary Key BMY program revenue is at risk from loss of patent exclusivity over the next several years. The company has turned to acquisitions to fortify its pipeline and revenue streams. BMY is relying on its pipeline of new products and recent acquisit...
News, Short Squeeze, Breakout and More Instantly...
Roche Holding Ltd ADR Company Name:
RHHBY Stock Symbol:
OTCMKTS Market:
Roche Holding Ltd ADR Website:
2024-07-23 05:48:00 ET Novo Nordisk (NYSE: NVO) is riding the Ozempic/Wegovy train straight to the bank. Eli Lilly (NYSE: LLY) is doing the same with Mounjaro and Zepbound. Both big drugmakers have multibillion-dollar obesity drug franchises that continue to grow rapidly. Sh...
2024-07-22 05:59:00 ET Both Pfizer (NYSE: PFE) and Roche Holdings (OTC: RHHBY) rank among the world's most powerful pharmaceutical companies. Yet neither is actively competing in the all-important market for weight loss drugs, which is currently being split between the likes...
– Two-year Phase III data presented at ASRS 2024 show Susvimo’s potential as an alternative to eye injections to treat diabetic macular edema (DME) and diabetic retinopathy (DR) – – Safety data were consistent with the known safety profile for Susvimo in people...